Form 4: Terns Pharmaceuticals Chief Medical Officer Sells Shares to Cover Tax Obligations

Terns Pharmaceuticals' Chief Medical Officer, Emil Kuriakose, sold 4,481 shares of common stock to cover taxes related to a vesting restricted stock unit award.

Summary

• Emil Kuriakose, the Chief Medical Officer of Terns Pharmaceuticals, sold 4,481 shares of common stock on January 2, 2025.
• The sale was executed to cover tax obligations associated with the vesting of a previously granted restricted stock unit award.
• The shares were sold at a weighted average price of $5.7146, with individual sales ranging from $5.65 to $5.80 per share.
• Following the transaction, Kuriakose directly owns 54,269 shares of Terns Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: The document describes a routine transaction for tax purposes, not indicative of any positive or negative sentiment towards the company's performance.

Industry Context

This is a routine transaction for company insiders to manage their tax liabilities related to stock-based compensation. It is common for executives to sell shares after vesting to cover taxes.

Comparison to Industry Standards

• Sales of shares by executives to cover tax obligations are a common practice across the pharmaceutical industry.
• Many companies use restricted stock units as part of their compensation packages, leading to similar tax-related sales.
• The sale price range is within the typical fluctuations seen in the market for similar companies.

Stakeholder Impact

• The sale of shares by an executive may have a minor impact on the stock price, but it is not expected to be significant.

Key Dates

Keywords

Terns Pharmaceuticals, insider trading, stock sale, Form 4, Emil Kuriakose, restricted stock unit, tax obligations, share sale